Bicara Therapeutics (NASDAQ:BCAX) Stock Rating Upgraded by BMO Capital Markets

Bicara Therapeutics (NASDAQ:BCAX) was upgraded by BMO Capital Markets to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

BCAX has been the topic of several other reports. Wells Fargo & Company lifted their price target on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 12th. Wall Street Zen upgraded shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. Morgan Stanley lifted their target price on Bicara Therapeutics from $37.00 to $39.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Finally, Mizuho upped their target price on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.64.

Bicara Therapeutics Stock Up 3.8%

Shares of BCAX opened at $25.86 on Tuesday. The stock has a market capitalization of $1.71 billion, a P/E ratio of -8.34 and a beta of -0.75. Bicara Therapeutics has a twelve month low of $10.30 and a twelve month high of $30.99. The company has a 50 day moving average of $26.44 and a 200-day moving average of $22.02.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting analysts’ consensus estimates of ($0.82). On average, sell-side analysts anticipate that Bicara Therapeutics will post -3.45 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Claire Mazumdar sold 10,000 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $279,800.00. Following the transaction, the chief executive officer directly owned 362,152 shares in the company, valued at $10,133,012.96. The trade was a 2.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 28,214 shares of the company’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72. Following the completion of the sale, the chief operating officer directly owned 182,177 shares in the company, valued at approximately $5,279,489.46. The trade was a 13.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 108,000 shares of company stock valued at $3,079,236 in the last quarter. Company insiders own 13.80% of the company’s stock.

Institutional Trading of Bicara Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Legal & General Group Plc boosted its stake in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Bicara Therapeutics during the fourth quarter worth $45,000. Larson Financial Group LLC boosted its position in Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after purchasing an additional 4,585 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.